|
TW505646B
(en)
*
|
1998-06-19 |
2002-10-11 |
Pfizer Prod Inc |
Pyrrolo [2,3-d] pyrimidine compounds
|
|
PA8474101A1
(es)
|
1998-06-19 |
2000-09-29 |
Pfizer Prod Inc |
Compuestos de pirrolo [2,3-d] pirimidina
|
|
PT1382339E
(pt)
*
|
1999-12-10 |
2008-02-06 |
Pfizer Prod Inc |
Composições que contêm derivados de pirrolo[2,3-d]- pirimidina
|
|
PL359563A1
(pl)
|
2000-06-26 |
2004-08-23 |
Pfizer Products Inc. |
Związki pirolo [2,3-d] pirymidynowe jako środki immunosupresyjne
|
|
US7547702B2
(en)
|
2000-09-20 |
2009-06-16 |
Ortho-Mcneil Pharmaceutical, Inc. |
4-amino-quinazolines
|
|
US7067550B2
(en)
*
|
2000-11-03 |
2006-06-27 |
Massachusetts Institute Of Technology |
Treatments for neurotoxicity in Alzheimer's Disease
|
|
DE10063294A1
(de)
*
|
2000-12-19 |
2002-07-04 |
Aventis Pharma Gmbh |
Substituierte Heterocyclo-Norbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
|
|
JP2004528295A
(ja)
*
|
2001-01-30 |
2004-09-16 |
サイトピア ピーティワイ リミテッド |
キナーゼ阻害方法
|
|
CZ20032416A3
(cs)
|
2001-02-12 |
2004-07-14 |
F. Hoffmann-La Roche Ag |
6-Substituované pyridopyrimidiny
|
|
US7301023B2
(en)
|
2001-05-31 |
2007-11-27 |
Pfizer Inc. |
Chiral salt resolution
|
|
GB0115393D0
(en)
*
|
2001-06-23 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
|
US7678805B2
(en)
|
2001-06-29 |
2010-03-16 |
Ab Science |
Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD)
|
|
WO2003002108A2
(en)
|
2001-06-29 |
2003-01-09 |
Ab Science |
Use of tyrosine kinase inhibitors for treating inflammatory diseases
|
|
DE60227709D1
(de)
*
|
2001-06-29 |
2008-08-28 |
Ab Science |
Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
|
|
CA2452371A1
(en)
|
2001-06-29 |
2003-01-09 |
Ab Science |
Use of tyrosine kinase inhibitors for treating allergic diseases
|
|
JP2005500041A
(ja)
|
2001-06-29 |
2005-01-06 |
アブ サイエンス |
強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤
|
|
GB0119249D0
(en)
|
2001-08-07 |
2001-10-03 |
Novartis Ag |
Organic compounds
|
|
US7323469B2
(en)
|
2001-08-07 |
2008-01-29 |
Novartis Ag |
7H-pyrrolo[2,3-d]pyrimidine derivatives
|
|
US7829566B2
(en)
|
2001-09-17 |
2010-11-09 |
Werner Mederski |
4-amino-quinazolines
|
|
PY0228255A
(es)
|
2001-12-06 |
2004-06-01 |
Pfizer Prod Inc |
Compuestos cristalinos novedosos
|
|
CA2472619A1
(en)
|
2002-01-10 |
2003-07-24 |
Bayer Corporation |
Fused pyrimidine derivates as rho-kinase inhibitors
|
|
MXPA04007191A
(es)
|
2002-01-23 |
2005-03-31 |
Bayer Pharmaceuticals Corp |
Derivados de pirimidina como inhibidores de rho-quinasa.
|
|
MXPA04007196A
(es)
|
2002-01-23 |
2005-06-08 |
Bayer Pharmaceuticals Corp |
Inhibidores de rho-quinasa.
|
|
GB0202679D0
(en)
*
|
2002-02-05 |
2002-03-20 |
Glaxo Group Ltd |
Novel compounds
|
|
EP1388541A1
(en)
|
2002-08-09 |
2004-02-11 |
Centre National De La Recherche Scientifique (Cnrs) |
Pyrrolopyrazines as kinase inhibitors
|
|
WO2004047843A1
(en)
|
2002-11-26 |
2004-06-10 |
Pfizer Products Inc. |
Method of treatment of transplant rejection
|
|
WO2005044835A1
(en)
*
|
2003-10-27 |
2005-05-19 |
Genelabs Technologies, Inc. |
METHODS FOR PREPARING 7-(2'-SUBSTITUTED-ß-D-RIBOFURANOSYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES
|
|
CA2545192A1
(en)
*
|
2003-11-25 |
2005-06-09 |
Pfizer Products Inc. |
Method of treatment of atherosclerosis
|
|
RU2373197C2
(ru)
*
|
2004-03-30 |
2009-11-20 |
Тайсо Фармасьютикал Ко., Лтд. |
Пиримидиновые производные, обладающие активностью в отношении мсн
|
|
US20110104186A1
(en)
|
2004-06-24 |
2011-05-05 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
|
JP2008505088A
(ja)
*
|
2004-06-29 |
2008-02-21 |
アムゲン インコーポレイティッド |
ＡＣＫ１およびＬＣＫ活性を調節するピロロ［２，３−ｄ］ピリミジン
|
|
EP1797054A2
(en)
|
2004-08-02 |
2007-06-20 |
OSI Pharmaceuticals, Inc. |
Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
|
|
MY179032A
(en)
|
2004-10-25 |
2020-10-26 |
Cancer Research Tech Ltd |
Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
|
|
AR054416A1
(es)
*
|
2004-12-22 |
2007-06-27 |
Incyte Corp |
Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
|
|
WO2006091450A1
(en)
*
|
2005-02-18 |
2006-08-31 |
Lexicon Genetics Incorporated |
4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
|
|
BRPI0610278A2
(pt)
|
2005-05-13 |
2010-06-08 |
Irm Llc |
compostos e composições como inibidores de proteìna cinase
|
|
CN102127078A
(zh)
|
2005-07-14 |
2011-07-20 |
安斯泰来制药株式会社 |
Janus激酶3的杂环类抑制剂
|
|
KR20080026654A
(ko)
|
2005-07-14 |
2008-03-25 |
아스텔라스세이야쿠 가부시키가이샤 |
헤테로시클릭 야누스 키나제 3 억제제
|
|
JP5119154B2
(ja)
|
2005-09-22 |
2013-01-16 |
インサイト・コーポレイション |
Ｊａｎｕｓキナーゼの四環系阻害剤
|
|
EP2532667A1
(en)
*
|
2005-09-30 |
2012-12-12 |
Vertex Pharmaceuticals Incorporated |
Deazapurines useful as inhibitors of janus kinases
|
|
TWI630207B
(zh)
|
2005-12-13 |
2018-07-21 |
英塞特控股公司 |
作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶
|
|
JP2009531443A
(ja)
*
|
2006-03-29 |
2009-09-03 |
フォールドアールエックス ファーマシューティカルズ インコーポレーティッド |
α−シヌクレイン毒性の抑制
|
|
WO2007125321A2
(en)
|
2006-04-25 |
2007-11-08 |
Astex Therapeutics Limited |
Purine and deazapurine derivatives as pharmaceutical compounds
|
|
EP2121692B1
(en)
|
2006-12-22 |
2013-04-10 |
Incyte Corporation |
Substituted heterocycles as janus kinase inhibitors
|
|
WO2008084861A1
(ja)
|
2007-01-12 |
2008-07-17 |
Astellas Pharma Inc. |
縮合ピリジン化合物
|
|
WO2008119792A1
(en)
*
|
2007-04-02 |
2008-10-09 |
Palau Pharma, S. A. |
Pyrrolopyrimidine derivatives as jak3 inhibitors
|
|
CL2008001709A1
(es)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
|
|
EP3070090B1
(en)
|
2007-06-13 |
2018-12-12 |
Incyte Holdings Corporation |
Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
|
|
DE102007027800A1
(de)
|
2007-06-16 |
2008-12-18 |
Bayer Healthcare Ag |
Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung
|
|
CA2705319C
(en)
*
|
2007-11-10 |
2019-01-15 |
Laurence Reid |
Systems and methods for workflow automation, adaptation and integration
|
|
MX2010005671A
(es)
*
|
2007-11-28 |
2010-06-25 |
Dana Farber Cancer Inst Inc |
Inhibidores de miristato de moleculas pequeñas contra bcr-abl y metodos de uso.
|
|
CN101981036B
(zh)
|
2008-02-06 |
2013-09-04 |
诺瓦提斯公司 |
吡咯并[2,3-d]嘧啶及其作为酪氨酸激酶抑制剂的用途
|
|
MX2010008198A
(es)
*
|
2008-02-25 |
2010-08-23 |
Hoffmann La Roche |
Inhibidores de cinasa de pirrolopirazina.
|
|
PL2288610T3
(pl)
|
2008-03-11 |
2017-12-29 |
Incyte Holdings Corporation |
Azetydynowe i cyklobutanowe pochodne jako inhibitory jak
|
|
WO2009115084A2
(de)
*
|
2008-03-20 |
2009-09-24 |
Schebo Biotech Ag |
Neue pyrrolopyrimidin-derivate und deren verwendungen
|
|
AU2009266806A1
(en)
*
|
2008-07-03 |
2010-01-07 |
Exelixis Inc. |
CDK modulators
|
|
CN102171211A
(zh)
*
|
2008-08-01 |
2011-08-31 |
拜奥克里斯特制药公司 |
用作jak3抑制剂的哌啶衍生物
|
|
EP2384326B1
(en)
*
|
2008-08-20 |
2014-04-23 |
Zoetis LLC |
Pyrrolo[2,3-d]pyrimidine compounds
|
|
US8385364B2
(en)
*
|
2008-09-24 |
2013-02-26 |
Nec Laboratories America, Inc. |
Distributed message-passing based resource allocation in wireless systems
|
|
CA3025627C
(en)
|
2009-04-20 |
2021-08-31 |
Auspex Pharmaceuticals, Inc. |
Piperidine inhibitors of janus kinase 3
|
|
AR076794A1
(es)
|
2009-05-22 |
2011-07-06 |
Incyte Corp |
Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
|
|
EP3643312A1
(en)
|
2009-05-22 |
2020-04-29 |
Incyte Holdings Corporation |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
|
|
EP2451813B1
(en)
|
2009-07-08 |
2014-10-01 |
Leo Pharma A/S |
Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors
|
|
TWI466885B
(zh)
*
|
2009-07-31 |
2015-01-01 |
Japan Tobacco Inc |
含氮螺環化合物及其醫藥用途
|
|
TW201111385A
(en)
*
|
2009-08-27 |
2011-04-01 |
Biocryst Pharm Inc |
Heterocyclic compounds as janus kinase inhibitors
|
|
AR078012A1
(es)
|
2009-09-01 |
2011-10-05 |
Incyte Corp |
Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
|
|
CN105541847B
(zh)
|
2009-10-09 |
2019-08-16 |
因西特控股公司 |
3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物
|
|
EA201290147A1
(ru)
|
2009-10-15 |
2012-11-30 |
Пфайзер Инк. |
Пирроло[2,3-d]пиримидиновые соединения
|
|
WO2011075334A1
(en)
|
2009-12-18 |
2011-06-23 |
Pfizer Inc. |
Pyrrolo[2,3-d]pyrimidine compounds
|
|
WO2011097087A1
(en)
|
2010-02-05 |
2011-08-11 |
Pfizer Inc. |
Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors
|
|
EP2360158A1
(en)
*
|
2010-02-18 |
2011-08-24 |
Almirall, S.A. |
Pyrazole derivatives as jak inhibitors
|
|
EP3050882B1
(en)
|
2010-03-10 |
2018-01-31 |
Incyte Holdings Corporation |
Piperidin-4-yl azetidine derivatives as jak1 inhibitors
|
|
TW201204732A
(en)
*
|
2010-07-09 |
2012-02-01 |
Leo Pharma As |
Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
|
|
US9034884B2
(en)
|
2010-11-19 |
2015-05-19 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
|
|
CN103415515B
(zh)
|
2010-11-19 |
2015-08-26 |
因塞特公司 |
作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物
|
|
RU2013136906A
(ru)
*
|
2011-01-07 |
2015-02-20 |
Лео Фарма А/С |
Новые производные сульфамидпиперазина в качестве ингибиторов протеинтирозинкиназы и их фармацевтическое применение
|
|
ES2547916T3
(es)
|
2011-02-18 |
2015-10-09 |
Novartis Pharma Ag |
Terapia de combinación de inhibidores de mTOR/JAK
|
|
EP2688890B1
(en)
|
2011-03-22 |
2017-08-30 |
Advinus Therapeutics Limited |
Substituted fused tricyclic compounds, compositions and medicinal applications thereof
|
|
AU2012255792A1
(en)
*
|
2011-05-17 |
2013-11-07 |
Principia Biopharma Inc. |
Azaindole derivatives as tyrosine kinase inhibitors
|
|
PE20140832A1
(es)
|
2011-06-20 |
2014-07-14 |
Incyte Corp |
Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
|
|
HK1198579A1
(en)
|
2011-08-10 |
2015-04-30 |
Novartis Pharma Ag |
Jak p13k/mtor combination therapy
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
CN104185420B
(zh)
|
2011-11-30 |
2017-06-09 |
埃默里大学 |
用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
|
|
DK2796460T3
(en)
*
|
2011-12-21 |
2018-08-27 |
Jiangsu Hengrui Medicine Co |
SEXUAL PYRROL HETEROARYL RING DERIVATIVES, METHOD OF PREPARATION AND MEDICAL APPLICATIONS THEREOF
|
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
|
EP2852595B1
(en)
|
2012-05-21 |
2016-06-22 |
Bayer Pharma Aktiengesellschaft |
Substituted benzothienopyrimidines
|
|
CN105732639A
(zh)
*
|
2012-06-29 |
2016-07-06 |
辉瑞大药厂 |
作为LRRK2抑制剂的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类
|
|
EP2875013B1
(en)
*
|
2012-07-17 |
2017-11-29 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Indolecarbonitriles as selective androgen receptor modulators
|
|
KR20150028299A
(ko)
*
|
2012-07-20 |
2015-03-13 |
조에티스 엘엘씨 |
야누스 키나제 (ｊａｋ) 억제제 투여요법
|
|
TW201412740A
(zh)
|
2012-09-20 |
2014-04-01 |
Bayer Pharma AG |
經取代之吡咯并嘧啶胺基苯并噻唑酮
|
|
EP2897962A1
(en)
|
2012-09-21 |
2015-07-29 |
Advinus Therapeutics Limited |
Substituted fused tricyclic compounds, compositions and medicinal applications thereof
|
|
CN102936251A
(zh)
*
|
2012-11-05 |
2013-02-20 |
上海毕得医药科技有限公司 |
一种吡咯并[2,3-d]嘧啶衍生物的制备方法
|
|
PL2919766T3
(pl)
|
2012-11-15 |
2021-10-04 |
Incyte Holdings Corporation |
Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
|
|
KR101683061B1
(ko)
*
|
2013-02-07 |
2016-12-07 |
한국과학기술연구원 |
ＪＡＫ-3 저해제로 유용한 ７Ｈ-피롤로[2,3-ｄ]피리미딘-4-싸이올 유도체
|
|
RS58245B1
(sr)
|
2013-02-22 |
2019-03-29 |
Pfizer |
Kombinacija derivata pirolo[2,3-d]pirimidina sa jednim ili više dodatnih sredstava kao inhibitor janus kinaza (jak)
|
|
CN105189509B
(zh)
|
2013-03-06 |
2017-12-19 |
因赛特公司 |
用于制备jak抑制剂的方法及中间体
|
|
EP2970119B1
(en)
*
|
2013-03-14 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
SG10201912203XA
(en)
|
2013-08-07 |
2020-02-27 |
Incyte Corp |
Sustained release dosage forms for a jak1 inhibitor
|
|
WO2015083028A1
(en)
|
2013-12-05 |
2015-06-11 |
Pfizer Inc. |
Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
|
|
EP3083618B1
(en)
|
2013-12-17 |
2018-02-21 |
Pfizer Inc |
Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
|
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
|
EP3180344B1
(en)
|
2014-08-12 |
2019-09-18 |
Pfizer Inc |
Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
|
|
ES2928757T3
(es)
|
2015-05-01 |
2022-11-22 |
Pfizer |
Acrilamidas de pirrolo[2,3-b]pirazinilo y epóxidos de las mismas como inhibidores de la Janus Quinasa
|
|
UA118822C2
(uk)
*
|
2015-05-29 |
2019-03-11 |
Вуксі Фортуне Фармасьютікал Ко., Лтд |
Інгібітор янус-кінази
|
|
KR101771219B1
(ko)
|
2015-08-21 |
2017-09-05 |
양지화학 주식회사 |
야누스 키나제 1 선택적 억제제 및 그 의약 용도
|
|
CN108137586B
(zh)
|
2015-09-14 |
2021-04-13 |
辉瑞大药厂 |
作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
|
|
CN106831779B
(zh)
*
|
2015-11-28 |
2019-07-19 |
南昌弘益药业有限公司 |
一类jak激酶抑制剂的新化合物
|
|
AU2017221193B2
(en)
|
2016-02-16 |
2019-03-14 |
Zoetis Services Llc |
Process for preparing 7H-pyrrolo (2, 3-d) pyrimidine compounds
|
|
CN107098908B
(zh)
*
|
2016-02-23 |
2021-01-08 |
欣凯医药科技(上海)有限公司 |
一种吡咯并嘧啶类化合物的制备方法和应用
|
|
CN117756789A
(zh)
|
2016-12-14 |
2024-03-26 |
英特维特国际股份有限公司 |
作为选择性Janus激酶抑制剂的氨基吡唑类化合物
|
|
JP6944496B2
(ja)
|
2018-10-22 |
2021-10-06 |
ファイザー・インク |
ピロロ［２，３−ｄ］ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体
|
|
MX2021005334A
(es)
*
|
2018-11-05 |
2021-06-23 |
Avista Pharma Solutions Inc |
Compuestos quimicos.
|
|
EP3906029A4
(en)
|
2018-12-31 |
2022-09-21 |
Biomea Fusion, LLC |
INHIBITORS OF MENIN-MLL INTERACTION
|
|
EA202191852A1
(ru)
|
2018-12-31 |
2022-03-18 |
Биомеа Фьюжн, Ллс |
Необратимые ингибиторы взаимодействия менин-mll
|
|
NL2022471B1
(en)
|
2019-01-29 |
2020-08-18 |
Vationpharma B V |
Solid state forms of oclacitinib
|
|
EP3946606B1
(en)
|
2019-03-27 |
2025-01-01 |
Insilico Medicine IP Limited |
Bicyclic jak inhibitors and uses thereof
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
JP2023554665A
(ja)
|
2020-12-18 |
2023-12-28 |
ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド |
ホウ素含有ピラゾール化合物、それらを含む組成物、それらの方法及び使用
|
|
AU2022325861A1
(en)
|
2021-08-11 |
2024-02-29 |
Biomea Fusion, Inc. |
Covalent inhibitors of menin-mll interaction for diabetes mellitus
|
|
IL310717A
(en)
|
2021-08-20 |
2024-04-01 |
Biomea Fusion Inc |
Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT
|
|
WO2023029943A1
(zh)
*
|
2021-09-03 |
2023-03-09 |
星药科技(北京)有限公司 |
一种芳杂环化合物及其制备方法和用途
|
|
WO2023055731A1
(en)
*
|
2021-09-28 |
2023-04-06 |
Sanford Burnham Prebys Medical Discovery Institute |
Inhibitors of serine/threonine protein kinase stk3 or stk4 and uses thereof
|
|
EP4452970A1
(en)
|
2021-12-24 |
2024-10-30 |
Intervet International B.V. |
Use of aminopyrazole compounds
|
|
GB202215117D0
(en)
*
|
2022-10-13 |
2022-11-30 |
Norwegian Univ Sci & Tech Ntnu |
Compound
|
|
GB202215132D0
(en)
*
|
2022-10-13 |
2022-11-30 |
Norwegian Univ Sci & Tech Ntnu |
Compound
|
|
TW202430528A
(zh)
|
2023-01-18 |
2024-08-01 |
美商拜歐米富士恩股份有限公司 |
Ｎ－［４－［４－（４－嗎啉基）－７ｈ－吡咯並［２，３－ｄ］嘧啶－６－基］苯基］－４－［［３（ｒ）－［（１－氧代－２－丙烯－１－基）氨基］－１－哌啶基］甲基］－２－吡啶甲醯胺的結晶形式作為ｍｅｎｉｎ－ｍｌｌ相互作用的共價抑制劑
|